514 related articles for article (PubMed ID: 23163287)
1. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
Offord S; Wong B; Mirski D; Baker RA; Lin J
J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
[TBL] [Abstract][Full Text] [Related]
2. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics.
Bera R; Offord S; Zubek D; Lau G; Lin J; Baker RA; Karson C
J Med Econ; 2013; 16(4):522-8. PubMed ID: 23360177
[TBL] [Abstract][Full Text] [Related]
3. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
[TBL] [Abstract][Full Text] [Related]
4. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
5. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
8. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
11. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia.
Lin J; Wong B; Offord S; Mirski D
J Behav Health Serv Res; 2013 Jul; 40(3):355-66. PubMed ID: 23579871
[TBL] [Abstract][Full Text] [Related]
12. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.
Baser O; Xie L; Pesa J; Durkin M
J Med Econ; 2015 May; 18(5):357-65. PubMed ID: 25525771
[TBL] [Abstract][Full Text] [Related]
13. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data.
Munday J; Greene M; Chang E; Hartry A; Yan T; Broder MS
Curr Med Res Opin; 2019 Jul; 35(7):1231-1239. PubMed ID: 30649965
[No Abstract] [Full Text] [Related]
14. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
Fu AZ; Pesa JA; Lakey S; Benson C
BMC Psychiatry; 2022 Apr; 22(1):250. PubMed ID: 35395757
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE
J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329
[TBL] [Abstract][Full Text] [Related]
16. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
17. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
18. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
[TBL] [Abstract][Full Text] [Related]
19. Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study.
Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
Clin Drug Investig; 2020 Apr; 40(4):355-375. PubMed ID: 32152867
[TBL] [Abstract][Full Text] [Related]
20. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
Lang K; Federico V; Muser E; Menzin J; Menzin J
J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
